# Metformin vs Tolvaptan for Treatment of Autosomal Dominant Polycystic Kidney Disease

> **NCT03764605** · PHASE3 · UNKNOWN · sponsor: **Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari** · enrollment: 150 (estimated)

## Conditions studied

- ADPKD

## Interventions

- **DRUG:** Metformin
- **DRUG:** Tolvaptan

## Key facts

- **NCT ID:** NCT03764605
- **Lead sponsor:** Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-01-30
- **Primary completion:** 2021-09-30
- **Final completion:** 2022-01-30
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2018-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03764605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03764605, "Metformin vs Tolvaptan for Treatment of Autosomal Dominant Polycystic Kidney Disease". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT03764605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*